

Karen Sue B Carlson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7381085/publications.pdf>

Version: 2024-02-01

31
papers

303
citations

1307594

7
h-index

940533

16
g-index

31
all docs

31
docs citations

31
times ranked

840
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. <i>Nature Communications</i> , 2019, 10, 3931.	12.8	178
2	Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia. <i>Blood Advances</i> , 2019, 3, 1499-1511.	5.2	21
3	Single-cell transcriptome reveals the novel role of T-bet in suppressing the immature NK gene signature. <i>ELife</i> , 2020, 9, .	6.0	19
4	Hematological Issues in Critically Ill Patients with Cancer. <i>Critical Care Clinics</i> , 2010, 26, 107-132.	2.6	18
5	Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 158-166.	1.3	10
6	Is Minimal Residual Disease Monitoring Clinically Relevant in Adults with Acute Myelogenous Leukemia?. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 109-115.	2.3	9
7	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
8	The Adult Murine Intestine is Dependent on Constitutive Laminin- β 1 Synthesis. <i>Scientific Reports</i> , 2019, 9, 19303.	3.3	8
9	Stem cell damage after chemotherapy- can we do better?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 31-39.	1.7	6
10	Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 659.e1-659.e6.	1.2	5
11	Neuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 154.	3.7	4
12	Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens. <i>Blood</i> , 2018, 132, 1232-1232.	1.4	3
13	Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 5068-5068.	1.4	3
14	A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2019, 134, 3837-3837.	1.4	3
15	A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 9-10.	1.4	3
16	Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals. <i>Blood</i> , 2016, 128, 2784-2784.	1.4	2
17	Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH α inhibitor therapy for AML. <i>British Journal of Haematology</i> , 2021, 194, 1083-1085.	2.5	1
18	Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome. <i>Blood</i> , 2019, 134, 4557-4557.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Regulation of Hematopoiesis By the Coagulation Receptor Thrombomodulin. <i>Blood</i> , 2015, 126, 4750-4750.	1.4	1
20	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 229-233.	1.3	0
21	Stem Cell Biology in Bone Marrow Transplantation. <i>Organ and Tissue Transplantation</i> , 2021, , 29-42.	0.0	0
22	Abstract 4184: Development of ixabepilone-induced CIPN is related to pre-treatment with paclitaxel in a mouse model. , 2010, , .		0
23	A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia. <i>Blood</i> , 2011, 118, 3030-3030.	1.4	0
24	Short time to ATRA administration and reduction of early mortality in patients with APL.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18020-e18020.	1.6	0
25	Identification of additional therapeutic options for <i>de novo</i> acute myeloid leukemia (AML) patient enabled by next generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2015, 33, e18027-e18027.	1.6	0
26	A statistical model for predicting neutropenic fever.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18050-e18050.	1.6	0
27	Physiologic Hematopoiesis Is Dependent on Stromal Expression of Laminin- α 3 β 1. <i>Blood</i> , 2015, 126, 3596-3596.	1.4	0
28	The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS. <i>Blood</i> , 2019, 134, 5430-5430.	1.4	0
29	Stem Cell Biology in Bone Marrow Transplantation. <i>Organ and Tissue Transplantation</i> , 2021, , 1-14.	0.0	0
30	Secondary Hematologic Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma Are Associated with a Distinct Mutational Profile. <i>Blood</i> , 2020, 136, 28-28.	1.4	0
31	Dependence on Schwann Cell-Derived Laminin- α 3 β 1 Differentiates Early Lymphoid and Myeloid Development. <i>Blood</i> , 2020, 136, 37-37.	1.4	0